Introduction {#s1}
============

Breast cancer is one of the most common malignancies diagnosed among women worldwide, including those living in East Asian countries. Genetic factors play an important role in the etiology of both sporadic and familial breast cancer [@pgen.1002532-Nathanson1]. In the past two decades, more than 1,000 reports have been published addressing the association between variants in candidate genes and breast cancer risk. However, only a few genetic risk factors have been confirmed for this common malignancy [@pgen.1002532-Zhang1]. Recent genome-wide association studies (GWAS) have identified approximately 20 common genetic susceptibility loci for breast cancer [@pgen.1002532-Easton1]--[@pgen.1002532-Fletcher1]. However, these newly-identified genetic factors, along with known high-penetrance breast cancer susceptibility genes explain less than 30% of the heritability for this cancer [@pgen.1002532-Zhang1], [@pgen.1002532-Fletcher2]. Furthermore, most GWAS were conducted among women of European ancestry, and many of the variants discovered in European-ancestry populations showed only a weak or no association with breast cancer in other ethnic groups [@pgen.1002532-Zheng2], [@pgen.1002532-Zheng3]. For example, only 8 of 12 breast cancer risk SNPs identified in women of European ancestry were directly replicated in Chinese population [@pgen.1002532-Long2]. Therefore, GWAS conducted in non-European women are needed to fully uncover the genetic basis for breast cancer susceptibility. Herein, we report results from a large GWAS of breast cancer conducted in East Asian women.

Results {#s2}
=======

A total of 19,091 female breast cancer cases and 20,606 female controls---including 23,891 Chinese, 11,907 Korean and 3,809 Japanese women---were included in the present study ([Table 1](#pgen-1002532-t001){ref-type="table"}). In Stage I, we analyzed 690,947 SNPs in 2,918 breast cancer cases and 2,324 community controls recruited from studies conducted in Shanghai, China ([Figure 1](#pgen-1002532-g001){ref-type="fig"}, [Text S1](#pgen.1002532.s012){ref-type="supplementary-material"}). Top 5,365 SNPs were investigated in Stage IIa including 1,613 Chinese cases and 1,800 Chinese controls recruited from studies conducted in Shanghai, China. Of the SNPs evaluated, 68 SNPs showed an association with breast cancer risk at *P*≤0.05 with the same direction as observed in Stage I. We performed a meta-analysis for the remaining 4,913 SNPs with data available from both Stage IIa and Stage IIb (2,359 Korean cases and 2,052 Korean controls). Twenty-six SNPs showed an association with breast cancer risk with P~meta~≤0.05 and the association was consistent among Stages I, IIa and IIb. These SNPs, along with the 68 SNPs mentioned above, were selected for Stage III replication in 4,712 cases and 4,496 controls. Finally, based on the results of the first three stages, 22 top SNPs were selected for Stage IV evaluation in 7,489 cases and 9,934 controls.

![Overview of the study design.](pgen.1002532.g001){#pgen-1002532-g001}
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###### Selected characteristics of studies participating in the Asia Breast Cancer Consortium.

![](pgen.1002532.t001){#pgen-1002532-t001-1}

  Study Stage[a](#nt101){ref-type="table-fn"}    Ethnicity   No. of cases   No. of controls      age[b](#nt102){ref-type="table-fn"}      Menopause (%)[c](#nt103){ref-type="table-fn"}   ER+ (%)
  --------------------------------------------- ----------- -------------- ----------------- ------------------------------------------- ----------------------------------------------- ---------
  **Stage I**                                                                                                                                                                            
  Shanghai-I                                      Chinese       2,918            2,324        51.7/50.3[d](#nt104){ref-type="table-fn"}                     42.9/41.7                      65.3
  **Stage II**                                                                                                                                                                           
  Shanghai-II (IIa)                               Chinese       1,613            1,800                        53.2/53.4                                     50.2/55.1                      62.5
  SeBCS-I (IIb)                                   Korean        2,359            2,052                        48.1/51.7                                     37.9/52.0                      61.9
  **Stage III**                                                                                                                                                                          
  Shanghai-III                                    Chinese       2,601            2,386        53.8/55.1[d](#nt104){ref-type="table-fn"}                     50.3/52.6                      64.9
  Taiwan                                          Chinese       1,066            1,065        51.5/47.5[d](#nt104){ref-type="table-fn"}                     52.3/39.9                      66.1
  Nagoya                                         Japanese        644              644                         51.4/51.1                                     48.5/48.5                      72.8
  Nagano                                         Japanese        401              401                         53.8/54.0                                     54.9/65.3                      74.6
  **Stage IV**                                                                                                                                                                           
  Nanjing                                         Chinese       1,786            1,837                        50.6/50.2                                     51.3/47.6                      55.7
  Tianjin                                         Chinese       1,297            1,585                        51.9/51.9                                     51.9/55.5                      44.2
  Guangzhou                                       Chinese        838              865                         49.0/49.2                                     41.8/51.9                      71.6
  NCC                                             Korean         505              504                         49.0/49.1                                     49.5/45.3                      65.0
  SeBCS-II                                        Korean         777             1,104                        47.5/47.7                                     36.3/37.3                      63.0
  KOHBRA/KoGES                                    Korean        1,397            3,209        40.5/50.3[d](#nt104){ref-type="table-fn"}                       23.3/                        62.8
  MEC                                            Japanese        889              830                         66.5/66.5                                                                    85.3
  **Total**                                                     19,091          20,606                                                                                                   

See the methods section for the full names of participating studies.

Mean value for cases/controls.

Percentage for cases/controls.

Significant at α = 0.01 level.

SNP rs9485372 showed a statistically significant association with breast cancer risk in each of the four stages ([Table 2](#pgen-1002532-t002){ref-type="table"}). The OR (95% CI) per A allele was 0.88 (0.81--0.95), 0.86 (0.81--0.92), 0.94 (0.88--1.00) and 0.90 (0.85--0.94), respectively, for stages I to IV. The association with this SNP was remarkably consistent across all but one small study ([Figure 2A](#pgen-1002532-g002){ref-type="fig"}). Pooled analysis of samples from all studies produced OR (95% CI) of 0.90 (0.87--0.92) and *P*-value of 3.8×10^−12^, which is substantially lower than the conventional genome-wide significance level of 5×10^−8^ based on conservative Bonferroni adjustment of multiple comparisons at α = 0.05, providing strong evidence for an association of this SNP with breast cancer risk.

![ORs per risk allele and 95% CIs for breast cancer associated with three SNPs by study site and ethnicity.\
A: rs9485372, B: rs9383951; and C: rs7107217.](pgen.1002532.g002){#pgen-1002532-g002}
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###### Summary of results for the three SNPs showing a statistically or marginally significant association in all four stages with breast cancer risk, the Asia Breast Cancer Consortium.

![](pgen.1002532.t002){#pgen-1002532-t002-2}

  SNP[a](#nt105){ref-type="table-fn"}    Position[b](#nt106){ref-type="table-fn"}     Study      No. of Cases/Controls   EAF (%)[c](#nt107){ref-type="table-fn"}   Per allele OR (95%CI) d   P value[d](#nt108){ref-type="table-fn"}
  ------------------------------------- ------------------------------------------ ------------ ----------------------- ----------------------------------------- ------------------------- -----------------------------------------
  rs9485372 (A/G)                                   149650567 (6q25.1)                                                                                                                      
                                                                                     Stage I          2,770/2,175                         43.5                        0.88(0.81--0.95)                     1.4×10^−3^
                                                                                     Stage II         3,930/3,818                         47.1                        0.86(0.81--0.92)                     6.3×10^−6^
                                                                                    Stage III         4,081/4,074                         43.2                        0.94(0.88--1.00)                        0.05
                                                                                     Stage IV         5,186/7,440                         46.2                        0.90(0.85--0.94)                     4.2×10^−5^
                                                                                    All stages       15,967/17,507                        45.4                        0.90(0.87--0.92)                     3.8×10^−12^
  rs9383951 (C/G)                                   152337306 (6q25.1)                                                                                                                      
                                                                                     Stage I          2,916/2,319                         11.4                        0.82(0.73--0.93)                     2.4×10^−3^
                                                                                     Stage II         3,948/3,836                         10.1                        0.90(0.81--1.00)                        0.06
                                                                                    Stage III         4,581/4,433                          9.7                        0.91(0.82--1.00)                        0.06
                                                                                     Stage IV         6,117/8,296                          9.6                        0.88(0.81--0.96)                     3.3×10^−3^
                                                                                    All stages       17,562/18,884                        10.0                        0.88(0.84--0.93)                     1.9×10^−6^
  rs7107217 (C/A)                                  128978900 (11q24.3)                                                                                                                      
                                                                                     Stage I          2,916/2,319                         31.4                        1.13(1.04--1.23)                     3.6×10^−3^
                                                                                     Stage II         3,929/3,839                         34.8                        1.11(1.04--1.18)                     2.1×10^−3^
                                                                                    Stage III         4,606/4,424                         35.2                        1.07(1.00--1.14)                        0.04
                                                                                     Stage IV         7,348/9,831                         37.4                        1.05(1.01--1.10)                        0.02
                                                                                    All stages       18,799/20,413                        35.8                        1.08(1.05--1.11)                     4.6×10^−7^

Effect/reference alleles based on forward strand.

From NCBI genome build 36.

Effect allele frequency in controls.

Adjusted for age and study sites.

Two other SNPs, rs9383951 and rs7107217, were also consistently replicated in each of the three replication sets. The C allele of rs9383951 was associated with decreased risk with OR (95% CI) of 0.82 (0.73--0.93), 0.90 (0.81--1.00), 0.91 (0.82--1.00), and 0.88 (0.81--0.96), respectively, for stages I to IV ([Table 2](#pgen-1002532-t002){ref-type="table"}). The P-value reached 1.9×10^−6^ in the pooled analysis of samples from all four stages. For SNP rs7107217, the ORs (95% CI) per C allele were 1.13 (1.04--1.23), 1.11 (1.04--1.18), 1.07 (1.00--1.14) and 1.05 (1.01--1.10), respectively, for stages I to IV, respectively ([Table 2](#pgen-1002532-t002){ref-type="table"}). Analyses with all subjects combined showed OR (95% CI) of 1.08 (1.05--1.11) and *P* value of 4.6×10^−7^. Again, the association of breast cancer risk with these two SNPs was very consistent across the vast majority of participating studies ([Figure 2B and 2C](#pgen-1002532-g002){ref-type="fig"}).

Stratified analyses showed that the associations with these three SNPs were consistent in all three East Asian populations, although the association for SNPs rs9485372 and rs7107217 was not significant for Japanese subjects, probably due to a small sample size ([Table 3](#pgen-1002532-t003){ref-type="table"}). Associations of these three SNPs with breast cancer risk were similar when stratified by menopausal or estrogen receptor status and none of the heterogeneity tests was statistically significant ([Table S1](#pgen.1002532.s004){ref-type="supplementary-material"}). No significant interaction was observed with other risk factors ([Table S1](#pgen.1002532.s004){ref-type="supplementary-material"}). After adjusted for the top 5 or 10 principal components, the results did not change significantly ([Table S2](#pgen.1002532.s005){ref-type="supplementary-material"}).

10.1371/journal.pgen.1002532.t003

###### Association of SNPs with breast cancer risk by ethnic groups, the Asia Breast Cancer Consortium.

![](pgen.1002532.t003){#pgen-1002532-t003-3}

  SNP              Study        No. of Cases/Controls   EAF (%)[a](#nt109){ref-type="table-fn"}   OR (95% CI)[b](#nt110){ref-type="table-fn"}   P value[b](#nt110){ref-type="table-fn"}  
  ----------- ---------------- ----------------------- ----------------------------------------- --------------------------------------------- ----------------------------------------- -------------
  rs9485372                                                                                                                                                                              
                  Chinese            9,922/9,644                         43.2                                  0.90(0.84--0.96)                            0.83(0.76--0.90)               3.5×10^−6^
                   Korean            5,006/6,825                         48.2                                  0.87(0.79--0.95)                            0.76(0.68--0.85)               6.0×10^−7^
               Chinese+Korean       14,928/16,469                        45.2                                  0.89(0.85--0.94)                            0.80(0.75--0.85)               9.4×10^−12^
                  Japanese           1,039/1,038                         47.5                                  0.93(0.76--1.13)                            0.84(0.66--1.07)                  0.15
                All studies         15,967/17,507                        45.4                                  0.89(0.85--0.94)                            0.80(0.75--0.86)               3.8×10^−12^
  rs9383951                                                                                                                                                                              
                  Chinese           10,625/10,180                        10.7                                  0.86(0.80--0.92)                            0.87(0.67--1.13)               3.4×10^−5^
                   Korean            5,011/6,833                          9.7                                  0.92(0.83--1.02)                            0.79(0.52--1.19)                  0.06
               Chinese+Korean       15,636/17,013                        10.3                                  0.88(0.83--0.93)                            0.86(0.69--1.07)               1.3×10^−5^
                  Japanese           1,926/1,871                          6.8                                  0.86(0.71--1.05)                            0.40(0.14--1.13)                  0.05
                All studies         17,562/18,884                        10.0                                  0.88(0.83--0.93)                            0.83(0.67--1.03)               1.9×10^−6^
  rs7107217                                                                                                                                                                              
                  Chinese           11,887/11,719                        32.3                                  1.09(1.03--1.15)                            1.14(1.05--1.25)               2.2×10^−4^
                   Korean            4,987/6,824                         38.7                                  1.13(1.04--1.23)                            1.19(1.06--1.34)               7.1×10^−4^
               Chinese+Korean       16,874/18,543                        34.6                                  1.10(1.05--1.15)                            1.16(1.08--1.24)               6.4×10^−7^
                  Japanese           1,925/1,870                         47.3                                  1.09(0.94--1.27)                            1.09(0.91--1.31)                  0.33
                All studies         18,799/20,413                        35.8                                  1.10(1.05--1.15)                            1.15(1.08--1.22)               4.6×10^−7^

Effect allele frequency in controls.

Adjusted for age and study sites.

Both SNPs rs9485372 and rs9383951 are located at chromosome 6q25.1, approximately 2.34 Mb and 350 kb from the SNP rs2046210 that we previously reported for breast cancer risk [@pgen.1002532-Zheng1]. None of these three SNPs, however, are in LD (r^2^\<0.1) in any of the three populations (Asian, European and Africans) as determined using data generated in the HapMap or any of the study populations included in the current study ([Table S3](#pgen.1002532.s006){ref-type="supplementary-material"} and [Figure S1](#pgen.1002532.s001){ref-type="supplementary-material"}). In an analysis including all 30,153 subjects who were genotyped for three SNPs in 6q25.1, all three SNPs remained strongly associated with breast cancer risk after mutual adjustment of the other 2 SNPs with P values of 1.4×10^−12^, 1.3×10^−4^, and 6.0×10^−39^ for SNPs rs9485372, rs9383951 and rs2046210, respectively ([Table S4](#pgen.1002532.s007){ref-type="supplementary-material"}). No significant interaction was observed for these three SNPs ([Table S5](#pgen.1002532.s008){ref-type="supplementary-material"}). We also created a genetic risk score (GRS) to evaluate the combined effect of three SNPs located in 6q25.1 ([Table S6](#pgen.1002532.s009){ref-type="supplementary-material"}). Compared with women carrying 0--1 risk variants, women carrying 6 variants had over two-fold increased risk with an OR (95% CI) of 2.36 (1.89--2.96) and a P value of 1.3×10^−47^.

A total of 376 SNPs were successfully imputed in the LD blocks including rs2046210 and rs9485372 and the whole *ESR1* gene with RSQ≥0.3 and minor allele frequency (MAF)≥0.05. Among them, 27 SNPs showed an association with breast cancer risk with P≤0.05 after adjusted for age, rs9485372, rs9383951 and rs2046210 ([Table S7](#pgen.1002532.s010){ref-type="supplementary-material"}). With the exception of rs4591859 and rs7776340 in the locus of rs2046210 and rs7768330 in the locus of rs9383921, all other SNPs are in the same LD block within the *ESR1* gene ([Figure S2](#pgen.1002532.s002){ref-type="supplementary-material"}). No additional SNP in the rs9485372 locus showed an association with breast cancer risk at p\<0.05 after adjusted for rs9485372, rs2046210, and rs9383921.

Discussion {#s3}
==========

In this large GWAS conducted in East-Asian women including 19,091 cases and 20,606 controls, we provided strong evidence for a novel breast cancer susceptibility locus represented by rs9485372 and suggestive evidence for two other loci, represented by SNPs rs9383951 and rs7107217.

We previously reported a genetic susceptibility locus at 6q25.1, represented by rs2046210, for breast cancer risk [@pgen.1002532-Zheng1]. The newly identified SNPs, rs9485372 and rs9383951, also are located at chromosome 6q25.1. However, these three SNPs are not in LD and are thus representing independent breast cancer susceptibility loci. All of them were associated with breast cancer risk after mutual adjustment of the other two SNPs. SNP rs9485372 is approximately 31 Kb upstream of the TGF-β activated kinase 1/MAP3K7 binding protein 2 (*TAB2*) gene ([Figure 3](#pgen-1002532-g003){ref-type="fig"}). The protein encoded by this gene is an activator of MAP3K7/TAK1, which is required for the IL-1 induced activation of NF-κB and MAPK8/JNK. The TGF-β pathway plays a major role in breast cancer development and progression [@pgen.1002532-Benson1]. The MAP kinases pathway is critical in regulating cell growth and cell death [@pgen.1002532-Davis1] and may contribute to the development of cancer [@pgen.1002532-Davis1]. Furthermore, the TAB2 protein is required for DNA damage-induced TAK1 activation, suggesting that TAB2 may play a role in DNA damage repair [@pgen.1002532-Hinz1]. Other genes in the region identified in the study included *SUMO4*, *LATS1*, *PPIL4*, and *UST*. However, given the proximity of the *TAB2* gene with rs9485372 and the important role of this gene in breast carcinogenesis, it is possible that the association between rs9485372 and breast cancer risk may be mediated through the *TAB2* gene. It is also possible that the association may be mediated through regulating the *ESR1* gene, located approximately 2.5 Mb from rs9485372. This possibility was highlighted by a recent study showing that several open reading frames in the 6q25.1 regions co-expressed with *ESR1* [@pgen.1002532-Dunbier1]. Further research is warranted to clarify the mechanism of the association identified in the study.

![A regional plot of the −log~10~P-values for SNPs at 6q25.1.\
The LD is estimated using data from HapMap Asian population. Also shown are the SNP Build 36 coordinates in kilobases (Kb), recombination rates in centimorgans (cM) per megabase (Mb) and genes in the region (below) based on the March 2006 UCSC genome browser assembly.](pgen.1002532.g003){#pgen-1002532-g003}

SNP rs9383951 is located in intron 5 of the *ESR1* gene, an important gene that has been documented to play a key role in breast cancer development and progression. Previous candidate gene studies have extensively evaluated two SNPs, rs2234693 (Pvull) and rs9340799 (XbaI), in the *ESR1* gene in relation to breast cancer risk; the results, however, have been inconsistent [@pgen.1002532-Zhang1]. Neither rs2234693 nor rs9340799 are in LD (r^2^\<0.01) with the SNPs discovered in the present study. To follow-up the lead from our previous study reporting a susceptibility locus at 6q25.1 for breast cancer [@pgen.1002532-Zheng1], two recent studies conducted among women of European descent identified rs3757318 and rs9397435 in relation to breast cancer risk [@pgen.1002532-Turnbull1], [@pgen.1002532-Stacey3]. These two SNPs are in strong LD (r^2^\>0.6 in Asians) with the SNP (rs2046210) we previously reported at 6q25.1 in East Asians but not in other populations. Again, these two SNPs are not in LD (r^2^\<0.01 in Asian, European and African populations) with rs9383951 and rs9485372 identified in this study. Although the association with rs9383951 did not reach the conventional genome-wide significance, the fact that this SNP is located in the *ESR1* gene strongly suggests a true association of this SNP with breast cancer risk.

SNP rs7107217 also showed a consistent association in all four stages, although the pooled *P*-value did not reach the conventional genome-wide significance level. This SNP is located at 11q24.3, 152 Kb downstream of the *BARX2* gene and 212 Kb upstream of the *TMEM45B* gene ([Figure S3](#pgen.1002532.s003){ref-type="supplementary-material"}). *BARX2* is a homeobox gene for which the mouse ortholog has been shown to influence cellular processes that control cell adhesion and cytoskeleton remodeling. It has been shown, BARX2 and estrogen receptor-alpha (ESR1) coordinately regulate the production of alternatively spliced ESR1 isoforms and control breast cancer cell growth and invasion [@pgen.1002532-Stevens1]. BARX2 also acts in a tumor suppressor and loss of heterozygosity of this gene, lead to poorer survival in patients with ovarian cancer [@pgen.1002532-Sellar1].

It could be ideal to increase the sample size in the discovery stage and simplify the replication stages of the study. However, like many other consortium projects, financial constraints and some logistical issues prevented us for achieving the maximum statistical power. Nevertheless, with approximately 40,000 cases and controls, our study represents the largest breast cancer genetic association study in East Asian women. This consortium will continue to provide valuable resources to identify additional novel susceptibility loci for breast cancer.

In summary, in this large GWAS conducted in East Asia women, we provided convincing evidence for an association with a novel independent susceptibility locus located at 6q25.1, near the *TAB2* gene. Our study also suggests that genetic variants in the *ESR1* gene and chromosome 11q24.3 may be related to breast cancer risk. Given that multiple independent breast cancer susceptibility loci have identified in our studies and studies conducted by others in 6q25.1 that harbors the *ESR1* gene, it is possible that 6q25.1 may represent an important region for breast cancer susceptibility.

Methods {#s4}
=======

Study populations {#s4a}
-----------------

Included in this consortium project were 19,091 cases and 20,606 controls from 14 studies ([Table 1](#pgen-1002532-t001){ref-type="table"}). Detailed descriptions of these participating studies and demographic characteristics of study participants are provided in [Text S1](#pgen.1002532.s012){ref-type="supplementary-material"}. Briefly, the consortium included 23,981 Chinese women, 11,907 Korean women, 3,809 Japanese women. The Chinese women were from 8 studies: Shanghai \[n = 13,642, Shanghai Breast Cancer Study, Shanghai Breast Cancer Survival Study (SBCSS), Shanghai Endometrial Cancer Study (SECS), Shanghai Women Health Study (SWHS)\] [@pgen.1002532-Zheng1], , Nanjing (n = 3,623) [@pgen.1002532-Liang1], Tianjin (n = 2,882) [@pgen.1002532-Zhang2], Taiwan (n = 2,131) [@pgen.1002532-Ding1], and Guangzhou (n = 1,703). The Korean women were from four studies \[Seoul Breast Cancer Study (SeBCS) (n = 6,292) [@pgen.1002532-Choi1], Korea NCC (n = 1,009), KoGES (n = 3,209) [@pgen.1002532-Cho1], and KOHBRA (n = 1,397) [@pgen.1002532-Han1]\]. The Japanese women were from three studies conducted in Hawaii and Los Angeles \[n = 1,719; Multiethnic Cohort Study (MEC) [@pgen.1002532-Kolonel1]\], Nagoya (n = 1,288) [@pgen.1002532-Hamajima1], and Nagano (n = 802) [@pgen.1002532-Itoh1] ([Table 1](#pgen-1002532-t001){ref-type="table"}). Approval was granted from relevant institutional review boards in all study sites; all included subjects gave informed consent.

Genotyping methods {#s4b}
------------------

The Genotyping protocol for Stage I has been described previously [@pgen.1002532-Zheng1]. Briefly, the initial 300 subjects were genotyped using the Affymetrix GeneChip Mapping 500K Array Set. The remaining 4,985 subjects were genotyped using the Affymetrix Genome-Wide Human SNP Array 6.0. We included one negative control and at least three positive quality control (QC) samples from the Coriell Cell Repositories (<http://ccr.coriell.org/>) in each of the 96-well plates for Affymetrix SNP Array 6.0 genotyping. A total of 273 positive QC samples were successfully genotyped, and the average concordance rate was 99.9% with a median value of 100%. The sex of all study samples was confirmed to be female. Genetically identical, unexpected duplicated samples were excluded, as were close relatives with a pair-wise proportion of identify-by-descent (IBD) estimate greater than 0.25. All samples with a call rate\<95% were excluded. The SNPs were excluded if: (i) MAF\<1%, (ii) call rate\<95%, or (iii) genotyping concordance rate\<95% in quality control samples. The final dataset included 2,918 cases and 2,324 controls for 690,947 markers. There are 21,223 SNPs that were on Affymetrix 500K Array Set but not on the Affymetrix SNP Array 6.0. These SNPs were excluded. SNPs on the Affymetrix 6.0 array but not on the Affymetrix 500k array were treated as missing data for those samples genotyped on using the Affymetrix 500k array. Similar results were obtained after excluding women genotyped by Affymetrix 500K Array Set from the analyses.

Genotyping for Stage IIa was completed using the Illumina iSelect platform. To compare the consistency between the Affymetrix and Illumina iSelect platforms, we also included 43 samples from Stage I that were genotyped by Affymetrix SNP 6.0. Similar to the QC procedures used in Stage I, the following criteria were used to exclude samples: (i) call rate\<95%; or (ii) unexpected duplicated samples based on IBD estimate. SNPs were excluded if: (i) call rate\<95%, or (ii) genotyping concordance rate\<95% in quality control samples when compared with Affymetrix 6.0 data. After QC, the mean concordance rate was 99.85% between Illumina iSelect and Affymetrix 6.0 genotyping.

Data for the SNPs analyzed in Stage IIb were extracted from the Korean GWAS genotyped using the Affymetrix Genome-Wide Human SNP Array 6.0 chip. A total of 30 QC samples were successfully genotyped, and the concordance rate was 99.83%. The sex of all samples was confirmed to be female. The SNPs were excluded if: (1) genotype call rate\<95%, (2) MAF\<1% in either the cases or controls, (3) deviation from HWE at *P*-value\<10^−6^, and (4) poor cluster plot in either the cases or controls.

Genotyping for Stage III and all samples from Koreans in Stage IV was completed using the iPLEX Sequenom MassArray platform in the Vanderbilt Molecular Epidemiology Laboratory. Included in each 96-well plate as QC samples were one negative control (water), two blinded duplicates, and two samples from the HapMap project. To compare the consistency between the Affymetrix and Sequenom platforms, we also genotyped 45 samples included in Stage I. The mean concordance rate was 99.67% for the blind duplicates, 98.88% for HapMap samples, and 99.52% between Sequenom and Affymetrix 6.0 genotyping. Data quality from the Hong Kong study was low and thus data from the study were excluded for the current analysis. Genotyping for two Chinese studies (Nanjing and Guangzhou) in Stage IV was completed using the iPLEX Sequenom MassArray platform at the Fudan University, Shanghai, China. Blind duplicate QC samples were included and the mean concordance rate was 98.70%. Genotyping for the Tianjin study in Stage IV was performed using TaqMan assays. Genotyping assay protocols were developed and validated at the Vanderbilt Molecular Epidemiology Laboratory, and TaqMan genotyping assay reagents were provided to investigators of the Tianjin study (Tianjin Cancer Institute and Hospital). For the MEC study, data for the three SNPs presented in this study were extracted from the GWA scan data generated using Illumina 660W. For SNPs not included on the chip, imputed data using HapMap as reference were extracted. Genotype frequencies for SNP rs9485372 deviated from HWE in controls (P = 0.004), therefore, this SNP was excluded in data analyses. Not all SNPs for Stage IV were genotyped in all studies included in Stage IV due to genotyping failure or the use of different genotyping platforms ([Table S8](#pgen.1002532.s011){ref-type="supplementary-material"}).

SNP selection for replication {#s4c}
-----------------------------

SNP selection for Stage II replication: Promising SNPs were selected for replication in Stage II based on the following criteria: 1) minor allele frequency (MAF)≥5%; 2) *P*\<0.02 in Stage I; 3) Hardy-Weinberg equilibrium (HWE) test *P*\>1.0×10^−6^ in controls; 4) not in strong linkage disequilibrium (LD) (r^2^\<0.5) with any of the previously confirmed breast cancer genetic risk variants or SNPs evaluated in our previous studies [@pgen.1002532-Zheng1], [@pgen.1002532-Long1]; and 5) high genotyping quality as indicated by very clear genotyping clusters checked manually. When multiple SNPs are in LD with r^2^≥0.5, one SNP with the lowest *P*-value was selected. In total, 6,303 SNPs were selected for replication. A total of 5,906 SNPs (93.7%) were successfully designed by Illumina and included in the iSelect array. After stringent QC procedures, data from 5,365 SNPs were considered high quality for association analyses in Stage IIa, which include 1,613 breast cancer patients and 1,800 controls recruited from Shanghai studies.

SNP selection for Stage III replication: Among the 5,365 SNPs successfully genotyped in Stage IIa, 68 SNPs were selected for Stage III replication in an independent set of 5,203 cases and 5,138 controls recruited from Shanghai and several other East Asian populations ([Table 1](#pgen-1002532-t001){ref-type="table"} and [Text S1](#pgen.1002532.s012){ref-type="supplementary-material"}). The selection criteria are: 1) an association with breast cancer risk in Stage IIa with P≤0.05; 2) the direction of the association consistent in both stages; and 3) P≤0.001 in the merged data of Stage I and IIa. During the course of Stage III genotyping, genome-wide association scan data from 2,359 cases and 2,052 controls were obtained from the Seoul Breast Cancer GWAS (Stage IIb). Therefore, we performed a meta-analysis of Stage IIa and IIb data. Of the 5,297 SNPs which were not selected initially for Stage III replication based on Stage IIa data alone, data were available for 4,913 SNPs in Stage IIb. Meta-analyses of these 4,913 SNPs from Stage IIa and IIb yielded 26 additional SNPs that showed an association at *P*≤0.05 and in the same direction among stages I, IIa, and IIb. These 26 SNPs were then added to the list of SNPs to be genotyped in Stage III.

SNP selection for Stage IV replication: Based on the results of the first three stages, 22 top SNPs were selected for Stage IV evaluation and genotyped in up to 17,423 additional subjects (7,489 cases and 9,934 controls) ([Table 1](#pgen-1002532-t001){ref-type="table"} and [Text S1](#pgen.1002532.s012){ref-type="supplementary-material"}).

Statistical analyses {#s4d}
--------------------

Case-control differences in selected demographic characteristics and major risk factors were evaluated using t-tests (for continuous variables) and Chi-square tests (for categorical variables). Associations between SNPs and breast cancer risk were assessed using odds ratios (ORs) and 95% confidence intervals (CIs) derived from logistic regression models. ORs were estimated for heterozygote and homozygote for the variant allele compared with homozygotes for the common allele. ORs were also estimated for the variant allele based on a log-additive model and adjusted for age, and study site, when appropriate. Stratified analyses by ethnicity, menopausal status, and estrogen receptor (ER) status were carried out. PLINK version 1.06 was used to analyze genome-wide data obtained in Stage I and the replication data in Stage IIa. Results from Stage IIb were also obtained from PLINK version 1.06. Meta-analyses of Stage IIa and Stage IIb were performed using a weighted z-statistics method, where weights were proportional to the square root of the number of individuals in each sample and standardized such that the weights added up to one. The z-statistic summarizes the magnitude and direction of the effect relative to the reference allele. An overall z-statistic and p value were then calculated from the weighted average of the individual statistics. Calculations were implemented in the METAL package (<http://www.sph.umich.edu/csg/abecasis/Metal>). Individual data were obtained from each study for Stage IV SNPs for a pooled analysis, which were conducted using SAS, version 9.2, with the use of two-tailed tests.

We first investigated the population structure by estimating inflation factor λ using all 690,947 SNPs SNPs that passed the QC. The inflation factor λ was estimated to be 1.042, suggesting that any population substructure, if present, should not have any appreciable effect on the results. Among the final 690,947 SNPs obtained in Stage I after QC, we generated a list of 196,471 SNPs with pairwise LD\<0.2 by using plink (<http://pngu.mgh.harvard.edu/~purcell/plink/>). Then, principal components were estimated based on these 196,471 SNPs using EIGENSTRAT [@pgen.1002532-Price1]. We then drew a plot for all Stage I and HapMap II subjects based on the first two principal components ([Figure 4](#pgen-1002532-g004){ref-type="fig"}). All study participants in Stage I were clustered very closely with HapMap Asians. The first 5 or 10 principal components were adjusted in the logistic regression analyses for evaluating associations of SNPs and breast cancer risk.

![Principal Component Analysis (PCA) based on the first two eigenvectors obtained by PCA.\
A: all individuals from Stage I and HapMap; B: breast cancer cases and controls from Stage I.](pgen.1002532.g004){#pgen-1002532-g004}

To evaluate the combined effect of SNPs located in chromosome 6q25.1 on breast cancer risk, we created a genetic risk score (GRS) by summing the number (0--2) of risk alleles that each woman carried for each of the three SNPs, including rs9383951, rs9485372, rs2046210. The GRS was constructed among those who had complete data for all three SNPs. We also did imputation using MACH (<http://www.sph.umich.edu/csg/abecasis/MACH/index.html>) with HapMap II Asian data as reference. LD structure was estimated from the flanking 100 kb of these three SNPs and the *ESR1* gene using data from HapMap II Asians ([Figure S1](#pgen.1002532.s001){ref-type="supplementary-material"}). All SNPs in the LD blocks including rs9485372, rs2046210 and rs9383951 and SNPs inside the *ESR1* gene were analyzed in relation to breast cancer risk with age, rs9485372, rs9383951 and rs2046210 adjusted.

Supporting Information {#s5}
======================
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Estimates of pairwise LD (r^2^) for common SNPs from HapMap II Asians for the SNPs located in 6q25.1. A: LD plot for the flanking 100 kb of SNP rs9485372. B: LD plot for the upstream 100 kb of SNP rs2046210 and the ESR1 gene.
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Estimates of pairwise LD (r^2^) from HapMap II Asian for the SNPs showing significant associations after adjusted for rs9485372, rs9383951 and rs2046210.
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A regional plot of the −log~10~P-values for SNPs at 11q24.3. The LD is estimated using data from HapMap Asian population. Also shown are the SNP Build 36 coordinates in kilobases (Kb), recombination rates in centimorgans (cM) per megabase (Mb) and genes in the region (below) based on the March 2006 UCSC genome browser assembly.
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